SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Short Interest Up 1,461.3% in July

SAB Biotherapeutics, Inc. (NASDAQ:SABSW) saw a large increase in short interest in the month of July. As of July 15th, there was short interest totaling 9,524 shares, an increase of 1,461.3% from the June 30th total of 610 shares. Based on an average daily volume of 264,901 shares, the days-to-cover ratio is presently 0.0 days.

SAB Biotherapeutics Stock Down 17.1%

Shares of NASDAQ:SABSW traded down $0.00 during trading on Friday, reaching $0.01. 9,797 shares of the stock were exchanged, compared to its average volume of 50,304. SAB Biotherapeutics has a 12-month low of $0.01 and a 12-month high of $0.06. The firm’s 50-day moving average price is $0.01 and its 200 day moving average price is $0.02.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biopharmaceutical company specializing in the development of fully human polyclonal antibody therapeutics. The company’s core technology, known as the Transchromosomic (Tc) Bovine platform, leverages genetically engineered cattle to produce large volumes of human antibodies in response to targeted antigens. These antibodies are designed to treat a range of infectious diseases and immunological disorders, offering a complementary approach to monoclonal antibodies and traditional vaccines.

The company’s lead programs focus on combating high-priority pathogens, including emerging coronaviruses and other viral threats.